18th Sep 2013 07:51
LONDON (Alliance News) - GW Pharmaceuticals PLC said Wednesday that it had completed a Phase 1 clinical trial of its GWP42006 treatment for epilepsy.
GWP42006 is a non-psychoactive cannabinoid extracted from the cannabis plant which GW says shows the ability to treat seizures in pre-clincal models of epilepsy with fewer side effects than current treatments.
Shares in the pharmaceutical company were trading flat at 71.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L